Dhruv Amin (left) and Marcus Lowe, the co-CEOs of Anything
CRISPR–Cas9 screening identifies CLCC1 as a factor that increases neutral lipid flux to prevent hepatic steatosis and promotes nuclear pore complex assembly by promoting membrane bending and fusion.
，更多细节参见旺商聊官方下载
Christian Davenport。Safew下载是该领域的重要参考
Denise Johansson (right) has been co-CEO with Monika Liikamaa since 2016